$1.25 EPS Expected for M.D.C. Holdings, Inc. (NYSE:MDC) This Quarter

Wall Street analysts forecast that M.D.C. Holdings, Inc. (NYSE:MDC) will announce $1.25 earnings per share for the current fiscal quarter, Zacks reports. Four analysts have made estimates for M.D.C.’s earnings, with estimates ranging from $1.21 to $1.28. M.D.C. reported earnings per share of $1.01 during the same quarter last year, which indicates a positive year-over-year growth rate of 23.8%. The business is scheduled to issue its next earnings report on Thursday, January 30th.

According to Zacks, analysts expect that M.D.C. will report full year earnings of $3.54 per share for the current financial year, with EPS estimates ranging from $3.50 to $3.57. For the next fiscal year, analysts anticipate that the business will post earnings of $4.20 per share, with EPS estimates ranging from $3.95 to $4.35. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for M.D.C..

M.D.C. (NYSE:MDC) last posted its earnings results on Wednesday, October 30th. The construction company reported $0.79 EPS for the quarter, missing the consensus estimate of $0.87 by ($0.08). M.D.C. had a net margin of 6.58% and a return on equity of 12.73%. The business had revenue of $750.27 million during the quarter, compared to analyst estimates of $767.23 million. During the same quarter in the prior year, the business earned $0.86 earnings per share. The firm’s revenue was down 2.1% compared to the same quarter last year.

MDC has been the subject of several research analyst reports. Wedbush upped their price objective on shares of M.D.C. from $35.00 to $41.00 and gave the stock a “neutral” rating in a report on Friday, September 13th. ValuEngine cut shares of M.D.C. from a “hold” rating to a “sell” rating in a research note on Tuesday. Zelman & Associates downgraded shares of M.D.C. from a “buy” rating to a “hold” rating in a research report on Thursday, October 31st. Cfra raised shares of M.D.C. from a “hold” rating to a “buy” rating in a research note on Thursday, October 31st. Finally, Raymond James upgraded shares of M.D.C. from an “outperform” rating to a “strong-buy” rating and raised their price objective for the company from $42.00 to $49.00 in a research note on Friday, September 13th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $44.00.

Shares of MDC traded up $0.56 during trading hours on Friday, reaching $39.70. 147,856 shares of the company’s stock traded hands, compared to its average volume of 552,521. M.D.C. has a twelve month low of $25.77 and a twelve month high of $46.84. The business’s fifty day simple moving average is $40.89 and its two-hundred day simple moving average is $37.76. The company has a debt-to-equity ratio of 0.66, a current ratio of 9.08 and a quick ratio of 1.83. The firm has a market capitalization of $2.43 billion, a price-to-earnings ratio of 10.82, a P/E/G ratio of 1.09 and a beta of 1.03.

The company also recently announced a quarterly dividend, which was paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th were paid a dividend of $0.30 per share. The ex-dividend date of this dividend was Tuesday, November 12th. This represents a $1.20 annualized dividend and a yield of 3.02%. M.D.C.’s dividend payout ratio is currently 32.70%.

In other M.D.C. news, Director Michael A. Berman sold 10,000 shares of M.D.C. stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $70.52, for a total value of $705,200.00. Following the transaction, the director now owns 148,218 shares in the company, valued at $10,452,333.36. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Raymond T. Baker sold 41,250 shares of the company’s stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $42.69, for a total value of $1,760,962.50. Following the completion of the transaction, the director now directly owns 45,462 shares in the company, valued at approximately $1,940,772.78. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 75,309 shares of company stock worth $3,381,670. 26.30% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Captrust Financial Advisors boosted its holdings in shares of M.D.C. by 86.0% in the second quarter. Captrust Financial Advisors now owns 1,306 shares of the construction company’s stock worth $43,000 after buying an additional 604 shares during the period. Flagship Harbor Advisors LLC raised its holdings in shares of M.D.C. by 141.2% during the third quarter. Flagship Harbor Advisors LLC now owns 1,802 shares of the construction company’s stock valued at $77,000 after acquiring an additional 1,055 shares during the period. Tower Research Capital LLC TRC acquired a new stake in shares of M.D.C. during the third quarter valued at approximately $79,000. Pacitti Group Inc. acquired a new stake in shares of M.D.C. during the third quarter valued at approximately $111,000. Finally, C M Bidwell & Associates Ltd. purchased a new stake in shares of M.D.C. in the 2nd quarter valued at approximately $90,000. 76.21% of the stock is owned by institutional investors and hedge funds.

M.D.C. Company Profile

M.DC Holdings, Inc, through its subsidiaries, engages in the homebuilding and financial service businesses. Its homebuilding operations include purchasing finished lots or developing lots for the construction and sale primarily of single-family detached homes to first-time and first-time move-up homebuyers under the Richmond American Homes name.

See Also: What is a CD ladder?

Get a free copy of the Zacks research report on M.D.C. (MDC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for M.D.C. (NYSE:MDC)

Receive News & Ratings for M.D.C. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for M.D.C. and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit